

SANOFI INDIA LIMITED

MINUTES OF THE SEVENTIETH ANNUAL GENERAL MEETING OF THE MEMBERS OF SANOFI INDIA LIMITED HELD ON WEDNESDAY, APRIL 29, 2026 FROM 3:30 P.M. (IST) TO 5.25 P.M. (IST) THROUGH VIDEO CONFERENCING / OTHER AUDIO-VISUAL MEANS ("VC/OAVM") FACILITY. THE MEETING WAS DEEMED TO BE HELD AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT SANOFI HOUSE, 117-B, SAKI VIHAR ROAD, POWAI, MUMBAI - 400072

Name of Director/Invitee	Designation	Location
Present:		
Mr. Aditya Narayan	Chairman and Independent Director	Sanofi Office, New Delhi
Mrs. Usha Thorat	Independent Director and Chairperson of the Nomination and Remuneration Committee, Corporate Social Responsibility Committee, Stakeholder Relationship Committee and Risk Management Committee	Kolhapur
Mr. Rahul Bhatnagar	Independent Director and Chairman of the Audit Committee	Sanofi Head Office – Mumbai
Ms. Rajani Kesari	Independent Director	Sanofi Head Office – Mumbai
Mr. Siraj Chaudhry	Independent Director	Sanofi Head Office – Mumbai
Mr. Vaibhav Karandikar	Non-Executive Director	Sanofi Head Office – Mumbai
Mr. Deepak Arora	Managing Director	Madrid
Mr. Rachid Ayari	Whole-time Director and Chief Financial Officer	Sanofi Head Office – Mumbai
Mr. Mahadev Gawade	Whole-time Director	Sanofi Head Office – Mumbai
Ms. Sudipta Chakraborty	Whole-time Director	Sanofi Head Office – Mumbai
In Attendance:		
Mr. Haresh Vala	Company Secretary & Compliance Officer	Sanofi Head Office – Mumbai

Invitees:		
Mr. Arun Ramdas	Partner at Price Waterhouse & Co. Chartered Accountants LLP, Statutory Auditors	Mumbai
Ms. Jigyasa Ved	Partner at Parikh & Associates, Company Secretaries, Secretarial Auditors	Mumbai
Mr. Harsh Bhatia	Partner at Kishore Bhatia and Associates, Cost Auditors	Mumbai
Mr. Sunny Gogiya	Partner, M/s. SGGGS and Associates, Scrutinizers	Sanofi Head Office – Mumbai

Members' Attendance & Quorum through VC/OAVM facility

- Total 72 members including authorized representatives were present at the meeting through VC / OAVM.
- Mr. Rachid Ayari and Mr. Haresh Vala represented Hoechst GmbH and Sanofi S.A., respectively holding cumulatively 1,39,09,587 shares (60.40%).

In accordance with the Companies Act, 2013 ("Act") read with the Secretarial Standards-2 on General Meetings ("SS-2") and the circulars issued by the Ministry of Corporate Affairs in this regard, the requisite quorum was present at the meeting.

Statutory Registers

The Statutory Registers and documents referred to in the Notice of the 70th Annual General Meeting ("AGM"/ "Meeting") as per requirement of the Act were open for inspection through electronic mode.

Details on VC / OAVM and E-voting

Mr. Haresh Vala, Company Secretary and Compliance Officer, welcomed the Members to the Company's 70th AGM. He stated that the Meeting was being held through VC / OAVM in accordance with the circulars issued by Ministry of Corporate Affairs, applicable provisions of the Act and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

He further informed the Members that the proceedings of the meeting were being webcasted live for all the shareholders as per the details provided in the Notice of the AGM and recorded for compliance purposes. He mentioned that in accordance with the provisions of the Act and SEBI Listing Regulations, the Members had been provided with the facility to exercise their right to vote by electronic means both through remote e-voting facility and e-voting at the AGM. The Members were apprised that the remote e-voting facility was made available to all the Members holding shares as on the cut-off date i.e. Wednesday, April 22, 2026, for the period commencing Saturday, April 25, 2026 from 9:00 a.m. (IST) to Tuesday, April 28, 2026 till 5:00 p.m. (IST).

He then requested the Members who had not cast their votes by means of the remote e-voting, to vote through the e-voting facility provided at the AGM, available until 30 minutes after the conclusion of the AGM. The Members who had already cast their vote by remote e-voting prior to the meeting would not be entitled to cast their votes again.

Mr. Haresh Vala informed the Members that the Board of Directors had appointed Mr. Gaurav Sainani, or failing him, Mr. Sunny Gogiya, Partners at M/s. SGGGS and Associates, Practising Company Secretaries as the Scrutinizer for the meeting and that based on the report of the Scrutinizer, the combined results of remote e-voting and the e-voting done at the Meeting would be announced and displayed on the website of the Company and also intimated to the Stock Exchanges within the statutory timeline.

Chairman of the meeting

Mr. Aditya Narayan, Chairman of the Company, took the chair and introduced himself. He then welcomed the Members to the AGM.

The Chairman then declared the meeting as validly convened, pursuant to fulfilment of the requisite quorum.

Introduction of Directors and Company Secretary

The Chairman introduced the Directors and Company Secretary present at the meeting.

Mr. Eric Mansion, Non-Executive Director, tendered his apologies for his inability to attend the AGM due to prior commitments.

The Chairman also introduced the representatives of Statutory Auditors, Secretarial Auditors, Cost Auditors and the Scrutinizers of the AGM.

He then apprised the Members on the flow of the AGM.

Integrated Annual Report and Notice of the AGM

The Notice of the AGM, Report of the Directors, the Statutory Auditors' Report on the Company's Annual Accounts for the financial year ended December 31, 2025, and the Secretarial Audit Report for the financial year ended December 31, 2025, all forming part of the Integrated Annual Report 2025, were taken as read.

The Chairman apprised the Members that the Statutory Auditors had issued an unqualified audit report on the Company's Annual Accounts for the year ended December 31, 2025. He further informed that the Members had appointed M/s. Parikh & Associates, Practising Company Secretaries, as the Secretarial Auditors, to conduct the Secretarial Audit of the Company for a period of 5 (five) years. The comments by the Secretarial Auditor for the year ended December 31, 2025, were self-explanatory.

Chairman's Speech

The Chairman thanked Mrs. Usha Thorat, Independent Director of the Company for her invaluable contribution, guidance to the Board and her perspectives strengthened the Company's governance in ways that would resonate for years to come, as her tenure was completing with effect from close of business hours of April 29, 2026.

He welcomed Ms. Rajani Kesari, Mr. Siraj Chaudhry, Independent Directors and Ms. Sudipta Chakraborty, Whole-time Director of the Company. He addressed that the appointment of Mr. Mahadev Gawade and Mr. Deepak Arora as Directors during the year had strengthened the Board of the Company.

He then thanked Mr. Rachid Ayari, who also filled in as Interim Managing Director from July 21, 2025 till October 26, 2025 in addition to his on-going role. He sincerely appreciated the contributions of Ms. Renee Amonkar and Mr. Rodolfo Hrosz, who have stepped down as Directors.

He further addressed that his tenure as an Independent Director would conclude with effect from close of business hours of April 29, 2026, and he would be handing over charge to Mr. Rahul Bhatnagar, who will assume the position of Chairman of the Board of the Company effective from April 30, 2026.

He then invited Mr. Deepak Arora, Managing Director, to give an update on the Company's performance for FY 2025.

Managing Director's Speech:

Mr. Deepak Arora, Managing Director, then addressed the Members on the key developments, operational and financial performance of the Company for FY 2025.

The extract of the speech is as follows:

Thank you, Chairman sir. With all gratitude also, a big thank you to you for your mentorship, guidance throughout these years, and today what we are, a lot of efforts and a lot of contribution goes to your able leadership to give us the guidance as we were moving forward. So, thank you again for all your leadership and mentorship.

Good afternoon, ladies and gentlemen. Thank you for joining us today and for the continuous trust you place in Sanofi India. It is a privilege to address you for the first time at the Annual General Meeting, particularly in a year when we mark seventy years of Sanofi's presence in India. As Sanofi India takes the lead today, for tomorrow, our role is clear: to translate today's opportunity into lasting, sustainable impact through innovation, access, and responsible execution.

In the financial year 2025, your Company delivered a stable performance. The diabetes portfolio delivered double-digit growth in the fourth quarter. We recorded revenue of operations of more than INR 18,000 million with EBITDA of INR 5,110 million and profit after tax of INR 3,267 million. A return on equity of plus 40.59% underscores the quality of our portfolio and the discipline with which we operate.

Alongside strengthening our capabilities and future readiness, we returned value through a dividend payout of INR 4,422 million. Accordingly, your Company has declared a final dividend of INR 48 per share in addition to the interim dividend of INR 75 per share. The total dividend for the year 2025 amounts to INR 123 per share.

While sales continue to represent nearly 94% of our revenue from operations, for the first time, exports declined to approximately 40% of total sales. This was anticipated due to the delay faced by Zentiva in obtaining manufacturing authorization from Indian authorities, following the divestment of Sanofi's Ankleshwar site. During this transition period, Sanofi India manufactured for Zentiva at its Goa facility.

As Zentiva successfully obtained and transitioned to their own operating licenses, the interim supply agreements came to an end, leading to a decrease in the export sales during the period. Diabetes remains at the core of our strategy. We accelerate growth in the public sector while gaining share of market in the private sector in the previous months.

We have established Sanofi's equity in diabetes injectable space, the moment was driven by continued strength of Lantus®, Toujeo®, and Apidra®, alongside the success of running Soliqua®, our premium offering in the premixed diabetes segment and space. Extending our reach into Tier 2 and Tier 3 markets, where enabling timely insulin initiation and supporting adherence through patient-focused programs remains a center to our go-to-market strategy.

While India faces a rising incidence of chronic diseases, our portfolio strategy remains heavily anchored on offering advanced and accessible treatment and therapies. We successfully developed positioning our legacy cardiovascular, central nervous system, as well as oral anti-diabetic portfolios, which have successfully transitioned into a partnership-driven marketing and distribution model to expand our partners and extensive network.

The revenue, as we talk about the diabetes portfolio, remains an important keystone and center for us to continue our growth as we move forward. During the year, we continued to reduce our environmental footprint through measurable actions. We achieved a reduction in Scope 1 and Scope 2 emissions, progressed our carbon footprint reduction journey, and met over 75% of energy requirements through renewable resources.

Responsible growth of us is inseparable from the responsibility to society. Our CSR initiatives reached approximately 2 million people through sustained programs in diabetes awareness, non-communicable diseases screening, community healthcare access, and education. With strong foundation and fundamentals, a clear strategy, and deeply committed team, we are well-positioned to continue delivering long-term value while addressing India's evolving healthcare needs.

On the completion of the tenures of Aditya sir - Chairman sir, and Mrs. Usha Thorat, Independent Director, I sincerely thank them for their stewardship over the years. I would also like to thank our employees for their dedication, our partners for their collaboration, and you, our shareholders, for continued confidence in us.

We deeply remain committed to India and its people. As we move into the next chapter of our journey, we will continue to chase the miracle of science, so that people across India can chase their dreams.

Thank you.

He then handed over to the Chairman to continue the meeting. The Chairman addressed to the Members on the future outlook and the evolving environment.

The extract of the speech is as follows:

Despite global economic volatility, the Indian pharmaceutical industry continues to demonstrate strong growth momentum.

India sustains its position as one of the fastest-growing large economies in the world, providing a robust, stable, and growing landscape for healthcare consumption supported by rising healthcare awareness, improved access, and favorable demographic trends. India represents one of the most significant growth opportunities in global healthcare, particularly in chronic disease management.

With our sharpened focus on diabetes care, combined with strategic partnerships and operational agility, we are now well-positioned to capture this opportunity in the time ahead. Government initiatives aimed at expanding healthcare coverage, promoting domestic manufacturing, and strengthening regulatory frameworks are creating both opportunities and heightened accountability.

Your Company stands on a strong foundation with a clear purpose, a committed team, and a future-ready strategy. Our continued focus on science-led innovation, expanding access to therapies, digital enablement, and sustainability positions us to deliver long-term value. At the same time, let's not - let's also keep in perspective as to what's happening globally and the world over.

As you all know, we live in an era of rapid and often unpredictable change. To flourish in such a time, it is critical that we adapt quickly. Real-time global connectivity, strengthened capital flows, geopolitical shifts, and evolving regulatory frameworks demand that businesses operate in this environment remain agile and adaptive. The pharmaceutical industry is no exception.

Innovation, speed, and responsiveness will define sustained leadership. In this context, your Company continues to benefit from the pioneering know-how and global expertise and best practices of its France-based parent, Sanofi. Over the past several years, we have deliberately reshaped our business. The demerger of consumer healthcare business into a separate entity with identical shareholding unlocked significant value for all the shareholders.

Our partnership-driven distribution model for established brands expanded market reach. New product introductions and strategic re-organization have made us leaner, fitter, and more competitive. We are also moving decisively towards integrating AI into our way of working, empowering our teams, enhancing productivity, and improving decision-making. Post-re-structuring, your Company is stronger, more focused, more agile, and better equipped to thrive in an increasingly competitive and technology-driven marketplace.

With these remarks, the Chairman concluded his opening statement and transitioned to the proposed Resolutions.

Resolutions passed at the meeting

The following 11 (eleven) Resolutions were proposed and passed at the meeting:

Ordinary business:

1. Adoption of the Annual Audited Financial Statements of the Company for the financial year ended December 31, 2025 including the Balance Sheet as at December 31, 2025, the Statement of Profit and Loss and the Cash Flow Statement for the financial year ended on that date and Reports of Board of Directors and Auditors thereon (Ordinary Resolution)

"RESOLVED THAT the Annual Audited Financial Statements of the Company for the financial year ended December 31, 2025, including Balance Sheet as at December 31, 2025, the Statement of the Profit and Loss and the Cash Flow Statement for the financial year ended on that date and Reports of the Board of Directors and Auditors thereon, be and are hereby approved and adopted."

2. Confirmation of the payment of interim dividend of Rs. 75 per equity share of Rs. 10 each and declaration of final dividend of Rs. 48 per equity share of Rs. 10 each for the financial year ended December 31, 2025 (Ordinary Resolution)

"RESOLVED THAT payment of interim dividend of Rs. 75 per equity share of Rs. 10 each on November 24, 2025 be and is hereby confirmed and a final dividend of Rs. 48 per equity share of the face value of Rs. 10 each, for the financial year ended December 31, 2025, be paid to:

- those Members whose names appear on the Register of Members of the Company on April 22, 2026; and
- those whose names appear as beneficial owners as at the close of business on April 22, 2026, as per details to be furnished by the National Securities Depository Limited and Central Depository Services (India) Limited."

3. Re-appointment of Mr. Vaibhav Karandikar (DIN: 09049375), who retires by rotation and being eligible, offers himself for re-appointment (Ordinary Resolution)

"RESOLVED THAT Mr. Vaibhav Karandikar (DIN: 09049375), who retires by rotation and being eligible for re-appointment, be and is hereby re-appointed as a Director of the Company."

4. Re-appointment of Mr. Eric Mansion (DIN: 10654588), who retires by rotation and being eligible, offers himself for re-appointment (Ordinary Resolution)

"RESOLVED THAT Mr. Eric Mansion (DIN: 10654588), who retires by rotation and being eligible for re-appointment, be and is hereby re-appointed as a Director of the Company."

Special business:

5. Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as a Director of the Company (Ordinary Resolution)

“RESOLVED THAT pursuant to the provisions of Sections 149, 152, 161 and other applicable provisions, if any, of the Companies Act, 2013 (‘the Act’) and Rules framed thereunder and Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) read with the Articles of Association of the Company, Ms. Sudipta Chakraborty (DIN: 07166912), who is appointed as an Additional Director of the Company by the Board of Directors, on the recommendation of the Nomination and Remuneration Committee, with effect from March 1, 2026 and in respect of whom the Company has received a notice in writing from a Member in terms of Section 160(1) of the Act, proposing her candidature for the office of a Director, be and is hereby appointed as a Director of the Company, liable to retire by rotation.

RESOLVED FURTHER THAT any one of the Director and the Company Secretary of the Company be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

6. Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as the Whole-time Director of the Company (Ordinary Resolution)

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 and other applicable provisions, if any, read with Schedule V of the Companies Act, 2013 (‘the Act’) and Rules framed thereunder and Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), read with the Articles of Association of the Company, and on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Ms. Sudipta Chakraborty (DIN: 07166912), be and is hereby appointed as the Whole-time Director of the Company for a term of 3 (three) years from March 1, 2026 to February 28, 2029, on such terms and conditions including remuneration as set out in the Explanatory Statement annexed to the Notice, with the power to the Board of Directors (hereinafter referred to as ‘the Board’ which term shall include the Nomination and Remuneration Committee of the Board) to alter and vary the terms and conditions of the said appointment and / or remuneration as it deemed fit, within the maximum limits of remuneration approved by the Members of the Company.

RESOLVED FURTHER THAT any one of the Director and the Company Secretary of the Company be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

7. Appointment of Ms. Rajani Kesari (DIN: 02384170) as an Independent Director for a term of 5 (five) consecutive years from April 1, 2026 to March 31, 2031 (Special Resolution)

“RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and 160 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (‘the Act’) and Rules framed thereunder and the applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and on the basis of recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the Members of the Company be and is hereby accorded for appointment of Ms. Rajani Kesari (DIN: 02384170), as an Independent Director of the Company, who has submitted a declaration that she meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations and in respect of whom a notice in writing under Section 160(1) of the Act has been received from a Member proposing her candidature for office of the Director of the Company be and is hereby appointed as an Independent Director on the Board of the Company for a term of 5 (five) consecutive years with effect from April 1, 2026, who shall not be liable to retire by rotation.

RESOLVED FURTHER THAT any one of the Director, and the Company Secretary of the Company be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

8. Appointment of Mr. Siraj Azmat Chaudhry (DIN: 00161853) as an Independent Director for a term of 5 (five) consecutive years from April 1, 2026 to March 31, 2031 (Special Resolution)

“RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and 160 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (‘the Act’) and the Rules framed thereunder and the applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’) (including any statutory modification(s) and/or re-enactment(s) thereof for the time being in force) and on the basis of recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the Members of the Company be and is hereby accorded for appointment of Mr. Siraj Azmat Chaudhry (DIN: 00161853), as an Independent Director of the Company, who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations and in respect of whom a notice in writing under Section 160(1) of the Act has been received from a Member proposing his candidature for office of the Director of the Company be and is hereby appointed as an Independent Director on the Board of the Company for a term of 5 (five) consecutive years with effect from April 1, 2026, who shall not be liable to retire by rotation.

RESOLVED FURTHER THAT any one of the Director, and the Company Secretary of the Company, be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

9. Approval of Material Related Party Transactions with Sanofi-Aventis Singapore Pte. Limited (Ordinary Resolution)

“RESOLVED THAT pursuant to Regulations 23(4), 2(1)(zc) and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’), the applicable provisions of the Companies Act, 2013 (‘the Act’), read with Rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Policy on Related Party Transactions of the Company, and based on the prior approval of the Audit Committee and recommendation of the Board of Directors of the Company, the approval of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’, which term shall be deemed to include any Committee constituted / empowered / to be constituted by the Board from time to time to exercise its powers conferred by this Resolution) to continue with the existing contract(s) / arrangement(s)/ transaction(s) and / or enter into and / or execute new contract(s) / arrangement(s) / transaction(s)(whether by way of an individual transaction or a series of transactions taken together), the details of which are provided in the Explanatory Statement to the Notice, with Sanofi-Aventis Singapore Pte. Ltd. (‘SASPL’), a related party of the Company under Regulation 2(1)(zb) of the Listing Regulations, on such terms and conditions as may be agreed between the Company and SASPL, for an aggregate value up to Rs.13,850 million, inter alia, for purchase and sale of goods including raw material, Active Pharmaceutical Ingredients and finished goods, export and sale of finished & intermediate products, business support services and other transactions for the purpose of business, whether by way of continuation(s) or renewal(s) or extension(s) or modification(s) of earlier arrangements / transactions or as fresh and independent transaction(s) or otherwise as may be mutually agreed upon between the Company and SASPL, to be entered during the financial year 2026, subject to such contract(s) / arrangement(s) / transaction(s) being carried out at arm’s length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board (including its Committees thereof), be and is hereby authorized to sign and execute all such documents, contracts, agreements, deeds and writings and to do and perform all such acts, deeds, matters and things, as may be necessary, including finalising the terms and conditions, methods and modes in respect thereof and finalising and executing necessary documents, including contract(s), agreement(s) and such other documents in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient to give effect to this Resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this Resolution.

RESOLVED FURTHER THAT the Board (including its Committees thereof), be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director, Committee or any other Officer(s) / Authorized Representative(s) of the Company to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT all actions taken by the Board (including its Committees thereof), or any person so authorized by the Board, in connection with any matter referred to or contemplated in any of the foregoing Resolution, be and are hereby approved, ratified and confirmed in all respects.”

10. Approval of Material Related Party Transactions with Sanofi Healthcare India Private Limited (Ordinary Resolution)

“RESOLVED THAT pursuant to Regulations 23(4),2(1)(zc) and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘the Listing Regulations’), the applicable provisions of the Companies Act, 2013 (‘the Act’), read with Rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the Policy on Related Party Transactions of the Company, and based on the prior approval of the Audit Committee and recommendation of the Board of Directors of the Company, the approval of the Members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the ‘Board’, which term shall be deemed to include any Committee constituted / empowered / to be constituted by the Board from time to time to exercise its powers conferred by this Resolution) to continue with the existing contract(s) / arrangement(s) / transaction(s) and / or enter into and / or execute new contract(s) / arrangement(s) / transaction(s) (whether by way of an individual transaction or a series of transactions taken together), the details of which are provided in the Explanatory Statement to the Notice, with Sanofi Healthcare India Private Limited (‘SHIPL’), a related party of the Company under Regulation 2(1)(zb) of the Listing Regulations, on such terms and conditions as may be agreed between the Company and SHIPL, for an aggregate value up to Rs.5,300 million, inter alia, for purchase of goods including raw material, Active Pharmaceutical Ingredients and finished goods, export and sale of finished & intermediate products, availing product development services, providing toll manufacturing services and business support services and other transactions for the purpose of business, whether by way of continuation(s) or renewal(s) or extension(s) or modification(s) of earlier arrangements / transactions or as fresh and independent transaction(s) or otherwise as may be mutually agreed upon between the Company and SHIPL, to be entered during the financial year 2026, subject to such contract(s) / arrangement(s) / transaction(s) being carried out at arm’s length and in the ordinary course of business of the Company.

RESOLVED FURTHER THAT the Board (including its Committees thereof), be and is hereby authorized to sign and execute all such documents, contracts, agreements, deeds and writings and to do and perform all such acts, deeds, matters and things, as may be necessary, including finalising the terms and conditions, methods and modes in respect thereof and finalising and executing necessary documents, including contract(s), agreement(s) and such other documents in this regard and deal with any matters, take necessary steps as the Board may, in its absolute discretion deem necessary, desirable or expedient to give effect to this Resolution and to settle any question that may arise in this regard and incidental thereto, without being required to seek any further consent or approval of the Members or otherwise to the end and intent that the Members shall be deemed to have given their approval thereto expressly by the authority of this Resolution.

RESOLVED FURTHER THAT the Board (including its Committees thereof), be and is hereby authorized to delegate all or any of the powers herein conferred, to any Director, Committee or any other Officer(s) / Authorized Representative(s) of the Company to give effect to the aforesaid Resolution.

RESOLVED FURTHER THAT all actions taken by the Board (including its Committees thereof), or any person so authorized by the Board, in connection with any matter referred to or contemplated in any of the foregoing Resolution, be and are hereby approved, ratified and confirmed in all respects.”

11. Ratification of remuneration payable to the Cost Auditors of the Company for the financial year ending December 31, 2026 (Ordinary Resolution)

“RESOLVED THAT pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013 read with Rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants (Firm Registration No. 00294), appointed by the Board of Directors on the recommendation of the Audit Committee, as Cost Auditors of the Company to conduct the audit of the cost records of the Company for the financial year ending December 31, 2026, amounting to Rs.4,60,000 (Rupees Four Lakh Sixty Thousand Only) plus applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the aforesaid audit, be and is hereby ratified.

RESOLVED FURTHER THAT any of one the Director, and the Company Secretary of the Company, be and are hereby severally authorized to take such steps and do all such acts, deeds, matters and things as may be considered necessary, proper and expedient to give effect to this Resolution.”

The Chairman informed the Members that since the meeting was being held through VC / OAVM facility and Resolutions were put to vote only through e-voting, the practice of proposing and seconding of Resolutions was not being followed.

Speakers Shareholders at the AGM

The Chairman informed the Members that the Company had received overwhelming response from shareholders to speak at the meeting.

The following Speaker Shareholders participated in the Meeting and presented their queries on the performance of the Company:

Mr. Santosh Chopra
Mr. Bimal Agarwal
Ms. Lekha Shah
Mr. Hiranand Parsram Kotwani
Mr. Hariram Chaudhary
Ms. Smita Shah
Mr. Bharat Shah
Mr. Ankit Agarwal
Mr. Ashish Bansal

Mr. Aspi Bhesania
Ms. Poonam Vakil
Mr. Vinod Agarwal

Some of the key remarks and suggestions made by the speaker shareholders at the Meeting were as follows:

- Recognition of the efforts of the Management and acknowledgement of good performance of the Company during FY 2025
- Appreciation of the Board on the dividends for the year 2025
- Request to the Board to consider Hybrid AGM, Plant Visit.
- Inquiry about Company's financials, Sales growth, CSR activities, new product launches, market share, future plans, related party transactions, artificial intelligence, etc.
- Clarification of the interests taken by the Company for the minority and majority shareholders.
- Recognition of the efforts of the Secretarial Team for sending Integrated Annual Report and assisting in joining the AGM.

The speaker shareholders conveyed their best wishes to Mr. Aditya Narayan and Mrs. Usha Thorat for a happy and fulfilling retired life, in appreciation of their valuable contributions to the Company.

The Chairman thanked the Members for their questions and participation.

Mr. Deepak Arora, Managing Director and Mr. Rachid Ayari, Whole-time Director and Chief Financial Officer then adequately responded to the queries raised by the speaker shareholders.

The key topics covered in their responses amongst others included:

- Digital transformation with the use of AI
- Promoting and creating awareness of the Product- through omnichannel and programs, either hybrid model, face-to-face and public sector channel
- Growth in the diabetes portfolio
- Compliance of the Related Party Transactions
- CSR spending
- Focus on operational efficiencies and pipeline progress
- Commitment to sustainability and environmental goals.

The Chairman while thanking Mr. Deepak Arora and Mr. Rachid Ayari for their response to bulk of the queries, requested the Members to write an e-mail to the Company Secretary, in case any queries remained unanswered.

The Chairman then requested Mrs. Usha Thorat to brief the Members.

The extract of her speech is as follows:

Thank you, Chairman, and good afternoon to all our shareholders. As I stand before you today at what will be my final Annual General Meeting as an Independent Director of Sanofi India, I'm filled with a deep sense of gratitude and pride. Over my tenure with this esteemed Company, I've had the privilege of serving on various Board committees.

Each of these roles has given me unique insights into the Company's commitment to excellence, transparency, and responsible business practices. What has consistently impressed me is Sanofi India's unwavering dedication to its core mission, improving healthcare outcomes for millions of Indians. Whether through our robust governance frameworks, our people-centric policies, our proactive risk management, or our meaningful CSR initiatives, this company has demonstrated time and again, that it places purpose alongside profit.

I have witnessed first-hand the integrity and professionalism of the management team, the dedication of our employees, and the Board's collective commitment to upholding the highest standards of corporate governance. The strong systems we have built together, the talented leadership team in place, and the clear strategic direction will continue to serve Sanofi India well in the years ahead.

To the shareholders, thank you, thank you for your trust. To my fellow Board members, thanking you for your collaboration and wisdom. To the management and employees, thank you for your dedication and excellence. It's been an honour and privilege to serve this remarkable company. I wish Sanofi India continued success in its mission of chasing the miracles of science.

The Chairman thanked Mrs. Thorat for her stellar contribution throughout her last decade association with the Company and then requested Mr. Rahul Bhatnagar to brief the Members.

The extract of his speech is as follows:

Well, thank you, Chairman, and good afternoon to all shareholders. Over the past several years, I've had the privilege of observing this Company up really close. Its values, its people, its resilience, and its relentless commitment to improving healthcare outcomes across India. What I have seen has only deepened my respect and admiration for this organization, quite frankly.

Now as I step into this role of Chairman, I do so with the utmost respect to the legacy built by Mr. Aditya Narayan. His decade-long stewardship has been nothing short of exemplary. I thank him sincerely for his leadership and for setting such a high standard of governance and vision.

To our shareholders, I assure you that I'm committed to upholding the values of transparency, accountability, and long-term value creation that have always defined Sanofi India, and I look forward to your support and co-operation in attempting this. To our employees, management, and partners, I look forward to working closely with you as we write the next exciting chapter for this company, for our company, in this country.

I'm honoured to lead this organization, and I'm fully committed to advancing its purpose, its people, and its promise.

The Chairman thanked Mr. Rahul Bhatnagar and appreciated his commitment to take the Company to take it to even stronger heights in time to come. He also thanked the Board Members for setting a standard which will help the Company in future.

The Chairman then invited those Members who had not yet exercised their voting rights-either through remote e-voting or e-voting during the AGM, to cast their votes within 30 minutes from the conclusion of the Meeting. The Members were informed that the consolidated result of remote e-voting and e-voting conducted at the AGM would be declared within stipulated time from the conclusion of the AGM.

The Company Secretary was authorized to receive the Scrutinizer's report and announce the voting results to the Stock Exchanges and to be uploaded on the websites of the Company and National Securities Depository Limited ("NSDL").

Vote of thanks

Finally, with no further matters to discuss, the Chairman, being his last AGM, formally concluded the Meeting by expressing sincere appreciation to the Board Members, Management Team, employees, healthcare community, partners and the Members for their presence and active engagement and special thanks to the Secretarial team for the seamless conduct of the AGM.

The meeting concluded at 5:25 p.m. (IST)

Scrutinizers Report

A brief summary of Scrutinizer's Report on the remote e-voting and the e-voting conducted at the AGM and the result of the voting thereon is enclosed as **Annexure-1**.

Date:

Place: Gurugram

sd/-
CHAIRMAN

Annexure – 1

Summary of Scrutinizer's Report

1. Cut-off date

The Voting rights were reckoned as on Wednesday, April 22, 2026, being the cut-off date for the purpose of ascertaining the entitlement of the members to vote through the remote e-voting and e-voting during the AGM.

2. E-voting Process

Process followed pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and MCA Circulars.

Agency: The Company had appointed NSDL as the agency for providing the remote e-voting platform.

Remote e-voting: The Remote e-voting facility was provided to the Members from Saturday, April 25, 2026, at 9:00 a.m. (IST) till Tuesday, April 28, 2026 at 5:00 p.m. (IST)

Electronic Voting at the AGM: Members who had not exercised their voting rights through remote e-voting, were provided the facility to vote electronically at the AGM until 30 minutes after the conclusion of the meeting.

3. Attendance

Date of AGM	April 29, 2026
Total number of shareholders on cut-off date (i.e. April 22, 2026)	80,754
No. of shareholders present in the meeting either in person or through proxy:	
Promoter and Promoter group	0
Public	0
No. of shareholders attended the meeting through Video Conferencing:	
Promoter and Promoter group	2
Public	70

4. Voting Results

The Consolidated Results with respect to the resolutions as set out in the Notice of the AGM dated March 25, 2026 is given below. Based on the aforesaid results, 11 (eleven) Resolutions as contained in the Notice of the AGM were passed with the requisite majority.

Notes:

- Voting rights on the shares transferred to 'Unclaimed Suspense Account' and those shares transferred to the 'Investor Education and Protection Fund' were frozen.
- The votes cast does not include invalid votes & abstained votes.
- All the aforesaid Resolutions were passed with requisite majority.

Resolution No. 1 - Ordinary Resolution:

To receive, consider and adopt the Annual Audited Financial Statements of the Company for the financial year ended December 31, 2025 including the Balance Sheet as at December 31, 2025, the Statement of Profit and Loss and the Cash Flow Statement for the financial year ended on that date and Reports of Board of Directors and Auditors thereon.

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5770078	95.4013	5770078	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5770078	95.4013	5770078	0	100.0000	0.0000
Public- Non Institutions	E-Voting	3072815	8407	0.2736	8285	122	98.5488	1.4512
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8407	0.2736	8285	122	98.5488	1.4512
Total		23030622	19688072	85.4865	19687950	122	99.9994	0.0006

Resolution No. 2 - Ordinary Resolution:

To confirm the payment of interim dividend of Rs. 75 per equity share of Rs. 10 each and to declare a final dividend of Rs. 48 per equity share of Rs. 10 each for the financial year ended December 31, 2025.

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
Public- Non Institutions	E-Voting	3072815	8382	0.2728	8280	102	98.7831	1.2169
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8382	0.2728	8280	102	98.7831	1.2169
Total		23030622	19691535	85.5015	19691433	102	99.9995	0.0005

Resolution No. 3 - Ordinary Resolution:

To re-appoint Mr. Vaibhav Karandikar (DIN: 09049375), who retires by rotation and being eligible, offers himself for re-appointment.

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5348493	425073	92.6376	7.3624
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5348493	425073	92.6376	7.3624
Public- Non Institutions	E-Voting	3072815	8312	0.2705	5928	2384	71.3186	28.6814
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	5928	2384	71.3186	28.6814
Total		23030622	19691465	85.5012	19264008	427457	97.8292	2.1708

Resolution No. 4 - Ordinary Resolution:

To re-appoint Mr. Eric Mansion (DIN: 10654588), who retires by rotation and being eligible, offers himself for re-appointment.

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5558880	214686	96.2816	3.7184
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5558880	214686	96.2816	3.7184
Public- Non Institutions	E-Voting	3072815	8309	0.2704	5905	2404	71.0675	28.9325
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8309	0.2704	5905	2404	71.0675	28.9325
Total		23030622	19691462	85.5012	19474372	217090	98.8975	1.1025

Resolution No. 5 - Ordinary Resolution:

Appointment of Ms. Sudipta Chakraborty (DIN:07166912) as a Director of the Company

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5689203	84363	98.5388	1.4612
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5689203	84363	98.5388	1.4612
Public- Non Institutions	E-Voting	3072815	8297	0.2700	5960	2337	71.8332	28.1668
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8297	0.2700	5960	2337	71.8332	28.1668
Total		23030622	19691450	85.5012	19604750	86700	99.5597	0.4403

Resolution No. 6 - Ordinary Resolution:

Appointment of Ms. Sudipta Chakraborty (DIN: 07166912) as the Whole-time Director of the Company

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5760544	13022	99.7745	0.2255
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5760544	13022	99.7745	0.2255
Public- Non Institutions	E-Voting	3072815	8312	0.2705	5925	2387	71.2825	28.7175
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	5925	2387	71.2825	28.7175
Total		23030622	19691465	85.5012	19676056	15409	99.9217	0.0783

Resolution No. 7 – Special Resolution:

Appointment of Ms. Rajani Kesari (DIN: 02384170) as an Independent Director for a term of 5 (five) consecutive years from April 1, 2026 to March 31, 2031

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
Public- Non Institutions	E-Voting	3072815	8312	0.2705	5900	2412	70.9817	29.0183
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	5900	2412	70.9817	29.0183
Total		23030622	19691465	85.5012	19689053	2412	99.9878	0.0122

Resolution No. 8 – Special Resolution:

Appointment of Mr. Siraj Azmat Chaudhry (DIN: 00161853) as an Independent Director for a term of 5 (five) consecutive years from April 1, 2026 to March 31, 2031

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total		13909587	13909587	100.0000	13909587	0	100.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5768911	4655	99.9194	0.0806
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total		6048220	5773566	95.4589	5768911	4655	99.9194
Public- Non Institutions	E-Voting	3072815	8312	0.2705	5882	2430	70.7652	29.2348
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total		3072815	8312	0.2705	5882	2430	70.7652
Total		23030622	19691465	85.5012	19684380	7085	99.9640	0.0360

Resolution No. 9 –Ordinary Resolution:

Approval of Material Related Party Transactions with Sanofi-Aventis Singapore Pte. Limited

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	0	0.0000	0	0	0.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	0	0.0000	0	0	0.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5763456	10110	99.8249	0.1751
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5763456	10110	99.8249	0.1751
Public- Non Institutions	E-Voting	3072815	8312	0.2705	8172	140	98.3157	1.6843
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	8172	140	98.3157	1.6843
Total		23030622	5781878	25.1052	5771628	10250	99.8227	0.1773

Resolution No. 10 –Ordinary Resolution:

Approval of Material Related Party Transactions with Sanofi Healthcare India Private Limited

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	0	0.0000	0	0	0.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	0	0.0000	0	0	0.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5763456	10110	99.8249	0.1751
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5763456	10110	99.8249	0.1751
Public- Non Institutions	E-Voting	3072815	8312	0.2705	8190	122	98.5322	1.4678
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	8190	122	98.5322	1.4678
Total		23030622	5781878	25.1052	5771646	10232	99.8230	0.1770

Resolution No. 11 –Ordinary Resolution:

Ratification of remuneration payable to the Cost Auditors of the Company for the financial year ending December 31, 2026

Category	Mode of voting	No. of shares held	No. of votes polled	% of Votes polled on outstanding shares	No. of votes – in favour	No. of votes – against	% of votes in favour on votes polled	% of Votes against on votes polled
		(1)	(2)	(3)=[(2)/(1)]*100	(4)	(5)	(6)=[(4)/(2)]*100	(7)=[(5)/(2)]*100
Promoter and Promoter Group	E-Voting	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	13909587	13909587	100.0000	13909587	0	100.0000	0.0000
Public-Institutions	E-Voting	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	6048220	5773566	95.4589	5773566	0	100.0000	0.0000
Public- Non Institutions	E-Voting	3072815	8312	0.2705	6298	2014	75.7700	24.2300
	Poll		0	0.0000	0	0	0.0000	0.0000
	Postal Ballot (if applicable)		0	0.0000	0	0	0.0000	0.0000
	Total	3072815	8312	0.2705	6298	2014	75.7700	24.2300
Total		23030622	19691465	85.5012	19689451	2014	99.9898	0.0102